Furthermore, through the use of selective inhibitors targeting IDO1 and COX-2, we successfully demonstrated that the melanoma cell line’s ability to impair iNKT cell activation and functions was attributed to the up-regulation of IDO1 expression and PGE2 production. The gene discussed is IDO1; the disease is melanoma.